Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Swanny Perrin"'
Autor:
David Montani, Laurent Bertoletti, Marie-Camille Chaumais, Swanny Perrin, Dominique Fabre, Ari Chaouat, Xavier Jaïs, Gérald Simonneau, Marc Humbert
Publikováno v:
European Respiratory Review, Vol 23, Iss 132, Pp 260-263 (2014)
Externí odkaz:
https://doaj.org/article/4563adbe98a64cee9228f0ff9ccfedb0
Autor:
D. Amar, Xavier Jaïs, Swanny Perrin, Olivier Sitbon, Marc Humbert, Laurent Savale, Caroline O’Connell, Gérald Simonneau, David Montani, Marie-Camille Chaumais
Publikováno v:
Expert Opinion on Pharmacotherapy. 16:2113-2131
Epoprostenol was the first targeted therapy available for the treatment of pulmonary arterial hypertension (PAH). Since then great advances in our knowledge of the disease have been made and the spectrum of therapeutic options for PAH has expanded. A
Autor:
Olivier Sitbon, Marc Humbert, Christophe Guignabert, Laurent Savale, Gérald Simonneau, Barbara Girerd, Swanny Perrin, Caroline O’Connell, David Montani, Marie-Camille Chaumais, Sven Günther
Publikováno v:
European Respiratory Journal. 46:1211-1214
More studies are needed to measure nasal decongestant exposure in patients with pulmonary arterial hypertension http://ow.ly/OFxs8
Autor:
Xavier Jaïs, Marc Humbert, Marie-Camille Chaumais, Dominique Fabre, David Montani, Ari Chaouat, Laurent Bertoletti, Gérald Simonneau, Swanny Perrin
Publikováno v:
European Respiratory Review, Vol 23, Iss 132, Pp 260-263 (2014)
To the Editor: Chronic thromboembolic pulmonary hypertension (CTEPH) is the most severe delayed complication after pulmonary embolism. Known risk factors of CTEPH include acute pulmonary embolism, the degree of pulmonary arterial occlusion, pulmonary
Autor:
Olivier Sitbon, David Montani, Marc Humbert, Marie-Camille Chaumais, Swanny Perrin, Gérald Simonneau
Publikováno v:
Expert Opinion on Drug Metabolism & Toxicology. 9:1193-1205
Introduction: Sildenafil citrate is a potent, selective phosphodiesterase type 5 inhibitor approved for the treatment of pulmonary arterial hypertension (PAH) and plays an important role in the management of the disease. Areas covered: In this review
Autor:
Philippe Camus, Julie Traclet, David Montani, Nicolas Favrolt, Vincent Cottin, Anne Roche, Xavier Jaïs, Marie-Camille Chaumais, Olivier Sitbon, Laurent Savale, Marc Humbert, Philippe Bonniaud, Swanny Perrin, Gérald Simmoneau
Publikováno v:
4.3 Pulmonary Circulation and Pulmonary Vascular Diseases.
Background: Some drugs are recognized risk factors of pulmonary arterial hypertension (PAH). Datas confirming a link between illicit drug use and PAH are limited. We tried to find out prevalence and caracteristics of PAH patients using illicit drugs
Autor:
Laurent Savale, Caroline Sattler, Sven Günther, David Montani, Marie-Camille Chaumais, Swanny Perrin, Xavier Jaïs, Andrei Seferian, Roland Jovan, Sophie Bulifon, Florence Parent, Gérald Simonneau, Marc Humbert, Olivier Sitbon
Publikováno v:
The European respiratory journal. 44(6)
Isolated cases of pulmonary arterial hypertension (PAH) in patients treated with interferon (IFN) α or β have been reported in the literature.The aim of this study was to describe all consecutive cases of PAH patients with a history of IFN exposure
Autor:
Marie-Camille Chaumais, Ph. Camus, N. Favrolt, Marc Humbert, O. Sitbon, A. Roche, Swanny Perrin, G Simonneau, Philippe Bonniaud, David Montani, Vincent Cottin, Xavier Jaïs, Laurent Savale, J. Traclet
Publikováno v:
Revue des Maladies Respiratoires. 33:A61
Introduction Certains medicaments ou toxiques sont des facteurs reconnus d’hypertension arterielle pulmonaire (HTAP). Les donnees confirmant le lien entre consommation de toxiques illicites et HTAP sont limitees. L’objectif de cette etude est de